The Evolving Treatment Landscape of Pancreatic Neuroendocrine Tumors
06/11/2013 - 06/11/2014
Alexandria Phan, MD; Matthew H. Kulke, MD; James C. Yao, MD; Jonathan S. Strosberg, MD; Pamela L. Kunz, MD
CME Released: 06/11/2013; Valid for credit through 06/11/2014
Click here for more information.
This activity is intended for medical oncologists, gastroenterologists, surgical oncologists, and any other healthcare providers involved in the diagnosis of pancreatic neuroendocrine tumors (PNETs) and the treatment and management of patients with this disease.
The goal of this activity is to review the diagnosis and treatment of resectable and nonresectable PNETs and the outcomes associated with these approaches.
Upon completion of this activity, participants will be able to:
- Review the current treatment approaches for localized, regional, and metastatic PNETs and the outcomes associated with these approaches
- Evaluate targeted molecular therapies (safety and efficacy) in the treatment of PNETs
- Integrate newly developed targeted agents into clinical practice for the treatment of unresectable, locally advanced or metastatic PNETs